clinical trial · NCT06378138
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
Beijing InnoCare Pharma Tech Co., Ltd.·phase3·recruiting·n = 226
Hematologic MalignanciesICP-248Orelabrutinib
brief summary
Evaluate the safety, tolerability and pharmacokinetics of ICP-248 in Combination with Orelabrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
started
May 15, 2024
primary completion
Nov 25, 2030
completion
Jul 25, 2031
last updated
Nov 21, 2025
official title
A Phase II/III Study of ICP-248 in Combination With Orelabrutinib in Patients With Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol